- Exo Biologics has launched a new Contract Development and Manufacturing Organisation (CDMO) specialising in exosomes, named ExoXpert.
- ExoXpert offers a Mesenchymal Stem Cell (MSC)-based exosome manufacturing platform used in European clinical trials.
- The launch of ExoXpert is set to meet the increasing worldwide demand for exosomes.
Exo Biologics, a Belgian biotech company, has announced the launch of ExoXpert, a new CDMO specialising in exosomes. This move comes as a response to the increasing global demand for exosomes, tiny vesicles that play a crucial role in cell-to-cell communication.
Exo Biologics has been at the forefront of exosome research and development. In 2023, the company developed ExoPulse, a state-of-the-art manufacturing platform that allows Good Manufacturing Practice (GMP) production, purification, and characterisation of exosomes. The company’s lead candidate, EXOB-001, was produced using ExoPulse and was approved for a phase I clinical trial in Europe.
The newly launched ExoXpert offers a MSC-based exosome manufacturing platform that has been used in European clinical trials. This platform is expected to provide a significant boost to the field of exosome research and application.
“The potential of exosomes continues to be demonstrated across the cell and gene therapy sector. As a result, exosome-based clinical trials have the potential to significantly increase in number, if industrial supply of exosomes can be met. Currently there is a lack of exosome production, manufacturing specialists and facilities to supply exosomes for both R&D and clinical trials,” said Romain de Rauville, Chief Business Officer, EXO Biologics.
